Subject(s)

Angioedema/virology , Coronavirus Infections/virology , Diabetes Mellitus, Type 2/virology , Hyperlipidemias/virology , Obesity/virology , Pneumonia, Viral/virology , Respiratory Insufficiency/virology , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Adult , Alanine/analogs & derivatives , Alanine/therapeutic use , Ampicillin/therapeutic use , Angioedema/immunology , Angioedema/physiopathology , Angioedema/therapy , Betacoronavirus/drug effects , Betacoronavirus/immunology , Betacoronavirus/pathogenicity , COVID-19 , Coronavirus Infections/immunology , Coronavirus Infections/physiopathology , Coronavirus Infections/therapy , Diabetes Mellitus, Type 2/immunology , Diabetes Mellitus, Type 2/physiopathology , Diabetes Mellitus, Type 2/therapy , Female , Humans , Hydroxychloroquine/therapeutic use , Hyperlipidemias/immunology , Hyperlipidemias/physiopathology , Hyperlipidemias/therapy , Intubation, Intratracheal , Obesity/immunology , Obesity/physiopathology , Obesity/therapy , Pandemics , Pneumonia, Viral/immunology , Pneumonia, Viral/physiopathology , Pneumonia, Viral/therapy , Respiration, Artificial , Respiratory Insufficiency/immunology , Respiratory Insufficiency/physiopathology , Respiratory Insufficiency/therapy , SARS-CoV-2 , Treatment Outcome